A pilot study to assess the safety and efficacy of the Transcend CyPass glaucoma implant in combination with cataract surgery in patients with open angle glaucoma

Transcend Medical, Inc.™ (USA)0 sites20 target enrollmentJune 17, 2010

Overview

No summary available.

Registry

who.int

Start Date

June 17, 2010

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional

Sex

All

Sponsor

Transcend Medical, Inc.™ (USA)

•1\. Patients must be age 18 or over, either sex
•2\. Patients must have diagnosis of primary open angle glaucoma or ocular hypertension (OHT). Also acceptable are patients diagnosed with open angle glaucoma associated with pseudoexfoliation syndrome or pigmentary glaucoma.
•3\. Candidacy for cataract surgery in the study eye as determined by the clinical judgment of the investigator
•4\. Patients who have had previous trabeculoplasty glaucoma procedures such as argon laser trabeculoplasty (ALT) or selective laser trabeculoplasty (SLT)
•5\. Patients must have intraocular pressure (IOP) of greater than or equal to 21 mmHg and less than or equal to 40 mmHg while on maximal tolerated medical therapy, documented at two sequential visits at any time of day, at least 48 hours apart, within 30 days prior to surgery
•6\. Patients must have sufficient space in the angle to accommodate the device
•7\. Patients must be able to understand the requirements of the study and be willing to follow study instructions, to provide written informed consent to participate, and who agree to comply with all study requirements, including the required study follow\-up visits

•1\. Patients with previous glaucoma surgery, including trabeculectomy or implantation of any aqueous shunt device, or the following glaucoma surgeries: viscocanulostomy, cyclophotocoagulation, or collagen implant
•2\. Patients with any ophthalmic surgery within 3 months in the eye to be treated
•3\. Patients with diagnosis of angle closure following penetrating keratoplasty, neovascular glaucoma, congenital glaucoma, developmental glaucoma or previous goniotomy
•4\. Patients with active uveitis within six months or other secondary glaucomas (other than pseudoexfoliation syndrome or pigmentary glaucoma)
•5\. Patients with best corrected visual acuity less than 20/200 in the fellow eye
•6\. Patients with clinically significant inflammation or infection within 6 months prior to the study
•7\. Patients with active diabetic retinopathy
•8\. Patients who have any uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of the investigator
•9\. Intolerance or hypersensitivity to topical anesthetics, mydriatics, or components of the device
•10\. A medical condition, serious illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow\-up